Sanguine's PHER-O2 Synthetic Red Blood Cell is Being Tested by Three Medical Schools in the United States and Canada
PASADENA, Calif.

For Sanguine Corp.
Michael Dancy, 801-746-3570 (Investor Relations)
medancy@allwest.net www.sanguine-corp.com

Sanguine Corp. (OTCBB: SGNC), a bio-pharmaceutical company focused on the development of an oxygen-carrying synthetic substitute for human red blood cells, today announced that its synthetic red blood cell substitute, PHER-O2, is being tested in various phases of animal toxicity trials being conducted by three medical schools in the United States and Canada. The focus of studies with PHER-O2 is its effectiveness in perfusion for pancreas preservation for transplantation. The universities include the University of Chicago, the University of Maryland and the University of Alberta (Canada).

These perfusion studies are aimed at enhancement of islets used in transplant action as amelioration for diabetes, the fastest growing disease in the United States and the world. Islet transplantation is done to improve human insulin production in Type 2 or adult onset diabetes.

Thomas Drees, Ph.D., chairman and CEO of Sanguine Corp., stated, "PHER-O2's predecessor, Fluosol DA, which is the only oxygen-carrying synthetic red blood cell substitute to have received FDA approval, underwent 34 animal trials as part of its FDA approval. We expect the trials conducted by the medical schools will, in part, satisfy some of the FDA testing requirements needed for Sanguine's animal trials."

Dr. Drees continued, "The successful completion of the studies will give Sanguine valuable information needed to commence our animal toxicity testing. We plan to begin the testing with a highly respected facility, which we are in the process of selecting."

Sanguine Corp. is a development-stage company focused on the research and development of PHER-O2, a synthetic red blood cell product with potential applications in a variety of specialties, including: transfusions, CAT scans, cardioplegia and the treatment of heart attacks, strokes, head and neck tumors and hemorrhagic shock. The company is also developing non-medical applications for its perfluorocarbon (PFC) product.

Sanguine's PHER-O2 is in Trials with Virginia Commonwealth University for the U.S. Navy
PASADENA, Calif.

Sanguine Corp.
Michael Dancy, 801-746-3570 (Investor Relations)
medancy@allwest.net www.sanguine-corp.com

Sanguine Corp. (OTCBB: SGNC), a bio-pharmaceutical company focused on the development of an oxygen-carrying synthetic substitute for human red blood cells, today announced that its synthetic red blood cell substitute, PHER-O2, is being used in trials conducted by Virginia Commonwealth University for the U.S. Navy on submarine crew and deep sea diving oxygenation treatment of the bends.

Thomas Drees, Ph.D., chairman and CEO of Sanguine Corp., noted, "In the medical treatment of the bends, the doctor typically will first treat immediate life threats, such as breathing problems or shock, if present. The diver will need high-flow oxygen and IV fluids. Blood and urine will be sent for laboratory tests to assess any blood clotting problems and hydration status. Additionally, the diver will need to go to a hyperbaric chamber for recompression. During this process the chamber becomes pressurized with air and oxygen based on prearranged protocols to simulate pressure depths of 30-60 feet. Typical dives last 140-270 minutes, but may last longer. At this depth or chamber pressures, bubbles are reduced in size or reabsorbed to ensure adequate blood flow. Recompression prevents further bubble formation and provides high amounts of oxygen to the injured tissues. Further treatments depend on how the diver responds to the initial treatment. The work under way with the U.S. Navy and Virginia Commonwealth University is an effort to use PHER-O2 in conjunction with increasing the blood oxygen levels in patients with the bends. One of the goals is to better enable the quick ascent of divers working on military operations."

Sanguine Corp. (OTC BB: SGNC), a bio-pharmaceutical company focused on the development of an oxygen-carrying synthetic substitute for human red blood cells, announced that it is conferring with the U.S. Army Medical Corps to develop a "golden hour" medical kit using PHER-O2. Such a kit could allow self-transfusion on the battlefield, thus helping to prevent bleeding to death, which is a major cause of fatality in combat, and which continues to be the case in Iraq, despite the improvements in front line medical care.

Thomas Drees, Ph.D., chairman and CEO of Sanguine Corp., stated, "In treating battlefield injuries, time is often critical to survivability. If a 'golden hour' kit can be developed, either self-transfusion or field transfusion by a medic could allow a wounded soldier a better opportunity at survival. This could be possible since PHER-O2 does not require refrigeration nor type and crossmatching, which is necessary with packed red cells."